Pulse Biosciences Past Earnings Performance
Past criteria checks 0/6
Pulse Biosciences's earnings have been declining at an average annual rate of -4.4%, while the Medical Equipment industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 39.9% per year.
Key information
-4.4%
Earnings growth rate
11.3%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 39.9% |
Return on equity | -95.2% |
Net Margin | n/a |
Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Dec 25We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth
Sep 04Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?
Mar 08Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO
Sep 20Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky
Apr 04Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?
Oct 29Pulse Biosciences gets Health Canada approval for CellFX System
Jun 09Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?
Mar 31Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?
Feb 24Pulse Biosciences establishes at-the-market equity program
Feb 04What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?
Jan 20Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication
Jan 12We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate
Dec 16Revenue & Expenses BreakdownBeta
How Pulse Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -42 | 16 | 28 |
30 Sep 23 | 0 | -39 | 14 | 24 |
30 Jun 23 | 0 | -47 | 16 | 21 |
31 Mar 23 | 0 | -51 | 20 | 20 |
31 Dec 22 | 1 | -59 | 26 | 21 |
30 Sep 22 | 2 | -65 | 32 | 22 |
30 Jun 22 | 2 | -61 | 35 | 24 |
31 Mar 22 | 2 | -62 | 34 | 26 |
31 Dec 21 | 1 | -64 | 34 | 29 |
30 Sep 21 | 1 | -62 | 31 | 30 |
30 Jun 21 | 0 | -61 | 29 | 31 |
31 Mar 21 | 0 | -57 | 27 | 29 |
31 Dec 20 | 0 | -50 | 24 | 26 |
30 Sep 20 | 0 | -50 | 24 | 26 |
30 Jun 20 | 0 | -49 | 24 | 25 |
31 Mar 20 | 0 | -49 | 24 | 25 |
31 Dec 19 | 0 | -47 | 23 | 25 |
30 Sep 19 | 0 | -42 | 19 | 23 |
30 Jun 19 | 0 | -41 | 19 | 22 |
31 Mar 19 | 0 | -39 | 19 | 20 |
31 Dec 18 | 0 | -38 | 20 | 17 |
30 Sep 18 | 0 | -37 | 22 | 15 |
30 Jun 18 | 0 | -34 | 21 | 13 |
31 Mar 18 | 0 | -31 | 20 | 11 |
31 Dec 17 | 0 | -26 | 16 | 10 |
30 Sep 17 | 0 | -20 | 11 | 8 |
30 Jun 17 | 0 | -15 | 8 | 7 |
31 Mar 17 | 0 | -11 | 4 | 6 |
31 Dec 16 | 0 | -10 | 3 | 6 |
30 Sep 16 | 0 | -8 | 2 | 5 |
30 Jun 16 | 0 | -6 | 2 | 4 |
31 Mar 16 | 0 | -4 | 2 | 3 |
31 Dec 15 | 0 | -3 | 2 | 2 |
30 Sep 15 | 0 | -2 | 1 | 2 |
Quality Earnings: PLSE is currently unprofitable.
Growing Profit Margin: PLSE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PLSE is unprofitable, and losses have increased over the past 5 years at a rate of 4.4% per year.
Accelerating Growth: Unable to compare PLSE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PLSE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.3%).
Return on Equity
High ROE: PLSE has a negative Return on Equity (-95.15%), as it is currently unprofitable.